Mediwound (NASDAQ:MDWD) and Exactus (OTCMKTS:EXDI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, dividends, earnings and risk.
This table compares Mediwound and Exactus’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Mediwound has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500. Comparatively, Exactus has a beta of 5.34, suggesting that its share price is 434% more volatile than the S&P 500.
Institutional and Insider Ownership
16.7% of Mediwound shares are held by institutional investors. 23.6% of Exactus shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This is a breakdown of recent ratings and recommmendations for Mediwound and Exactus, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Mediwound currently has a consensus target price of $6.25, indicating a potential upside of 64.47%. Given Mediwound’s higher probable upside, equities analysts clearly believe Mediwound is more favorable than Exactus.
Valuation & Earnings
This table compares Mediwound and Exactus’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Mediwound||$31.79 million||3.25||$4.95 million||$0.08||47.50|
Mediwound has higher revenue and earnings than Exactus.
Mediwound beats Exactus on 8 of the 12 factors compared between the two stocks.
Mediwound Company Profile
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Exactus Company Profile
Exactus, Inc., is a farmer and manufacturer of hemp-derived phytocannabinoid products. The company sells its CBD products through its Green Goddess brand and third-party resellers. Exactus is engaged in producing industrial hemp from farms in Oregon and plans to extract and manufacture directly through cGMP facilities. Industrial hemp is a type of cannabis, defined by the federal government as having THC (tetrahydrocannabinol) content of 0.3 percent or less. THC is the psychoactive compound found in cannabis.
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.